Pharmaceutical development company Nuformix PLC (LSE:NFX) recently presented NXP002, the company’s proprietary new form of tranilast, to a well-attended convergence of potential licensing partners at the European Respiratory Society (ERS) Congress in Barcelona.
The NXP002 programme is being developed as a novel inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF), and is targeting unmet medical needs in fibrosis and oncology.
In a pre-clinical update, Nuformix stated that:
- NXP002 can be delivered in-vivo by a range of nebulisers at the optimum particle size
- very high doses appear to be well-tolerated and
- an in-vivo dose response was observed for inflammatory and fibrotic biomarkers that is consistent with previous ex-vivo human IPF tissue studies
Executive director Dr Dan Gooding said: "Our first attendance at ERS has introduced our lead programme to major respiratory players, whilst generating valuable intelligence, allowing us to maintain and develop our current market-orientated development strategy.
“I am confident that our revised pre-clinical strategy will maximise the value of our IP estate and will generate further compelling data to support both progression and partnering of NXP002.”
Results will continue to be generated throughout 2022 with further updates to be announced in due course.